What are the different types of thalassemia and how are they diagnosed?

Types of Thalassemia and Their Diagnosis

Thalassemias are classified into alpha and beta types based on which globin chain is deficient, with diagnosis requiring a combination of complete blood count showing microcytic hypochromic anemia (MCV <80 fL), hemoglobin analysis, and molecular DNA testing to identify specific mutations. 1, 2, 3

Classification by Globin Chain Defect

Beta-Thalassemia

Beta-thalassemia results from mutations in the HBB gene on chromosome 11, with over 200 pathogenic variants causing either reduced (β⁺) or absent (β⁰) beta-globin synthesis. 1 The disorder follows autosomal recessive inheritance, requiring homozygosity or compound heterozygosity for severe disease. 1

Clinical severity categories include:

• Beta-thalassemia trait (carrier state): Microcytic hypochromic anemia with MCV <80 fL that does not respond to iron supplementation 1, 4
• Beta-thalassemia major (transfusion-dependent): Requires >8 transfusion events per year in adults, with life-threatening anemia beginning at 1-2 years of age as fetal hemoglobin declines 5, 1
• Beta-thalassemia intermedia (non-transfusion-dependent): Less severe disease that may require episodic transfusions but not regular lifelong transfusions 5, 6

Alpha-Thalassemia

Alpha-thalassemia is caused by reduced or absent alpha-globin chain synthesis and is most prevalent in Southeast Asian populations. 1 The severity depends on the number of alpha-globin genes deleted (normally four genes total). 7, 6

Clinical severity by gene deletion:

• Silent carrier (one-gene deletion): Asymptomatic with normal hematologic parameters 6
• Alpha-thalassemia trait (two-gene deletion): Mild microcytic anemia with MCV <80 fL 1, 7
• Hemoglobin H disease (three-gene deletion): Hemolytic anemia requiring CBC monitoring every 3-6 months 1, 7
• Alpha-thalassemia major/Hb Bart's (four-gene deletion): Results in hydrops fetalis and fetal demise, accounting for 28-55% of non-immune hydrops fetalis in Southeast Asian populations 5, 1, 7

Functional Classification

Modern classification is based on transfusion dependence rather than traditional terminology: 2

• Transfusion-Dependent Thalassemia (TDT): Includes beta-thalassemia major, severe Hb H disease, and severe Hb E/β-thalassemia—patients require regular transfusions to survive 1, 2
• Non-Transfusion-Dependent Thalassemia (NTDT): Includes beta-thalassemia intermedia, most Hb H disease, and mild Hb E/β-thalassemia—patients do not require regular transfusions 1, 2

Diagnostic Approach

Initial Screening

Begin with complete blood count showing characteristic microcytic hypochromic parameters: 3

• MCV markedly reduced (60-70 fL) and MCH 19-23 pg in beta-thalassemia carriers 3
• MCV slightly to moderately reduced in alpha-thalassemia carriers 3
• Red blood cell count is increased in both alpha-thalassemia 1 and beta-thalassemia 8

Critical pitfall: Always check serum ferritin to exclude iron deficiency before attributing microcytosis to thalassemia trait, as iron deficiency can coexist or mimic thalassemia. 4, 3

Hemoglobin Analysis

HbA2 determination is the most decisive test for beta-thalassemia carrier detection: 3

• Elevated HbA2 (>3.5%) confirms beta-thalassemia trait 3
• In alpha-thalassemia, HbA2 can be lower than normal, which assumes significance when iron deficiency is excluded 3
• Hemoglobin electrophoresis identifies abnormal hemoglobin variants 2, 3

Molecular DNA Testing

DNA analysis is essential for definitive diagnosis: 7, 3

• Not required to confirm beta-thalassemia carrier status but necessary to confirm alpha-thalassemia carrier status 3
• Detection of common deletions or point mutations identifies specific genetic defects 5, 7
• Essential for predicting severe transfusion-dependent versus intermediate-to-mild non-transfusion-dependent cases 3

Parental Screening Algorithm

For couples at risk, screen both parents with MCV measurement—values <80 fL suggest carrier status and warrant further testing. 5, 7

If both parents are carriers, proceed with prenatal diagnosis using: 7

• Amniocentesis or chorionic villus sampling for DNA analysis 5, 7
• Fetal blood sampling to detect abnormal Bart's hemoglobin in alpha-thalassemia major 5
• Middle cerebral artery Doppler to assess for fetal anemia (PSV >1.5 MoM indicates anemia) 5, 7

Common Diagnostic Pitfalls

Do not prescribe iron supplementation to patients with confirmed thalassemia trait—it provides no benefit and may cause unnecessary iron accumulation. 1, 4 The most clinically important distinguishing feature is that anemia in thalassemia trait does NOT respond to iron therapy despite compliance. 4

Do not miss the diagnosis in pregnant women of appropriate ancestry (Mediterranean, Middle Eastern, Southeast Asian, African) who have persistent mild anemia unresponsive to prenatal iron supplementation. 4 Failure to consider ethnicity leads to missed diagnoses. 4, 7

Recognize that newborns are asymptomatic because fetal hemoglobin does not require beta-globin chains—clinical symptoms emerge between 1-2 years of age. 1 This timing is critical for early diagnosis and treatment initiation before life-threatening complications develop. 1